CD8A and neoplasm: The rationale of immune checkpoint inhibitor therapy is based on the anti-tumor function of tumor reactive T cells (CD8+ cytotoxic T lymphocytes) (8), which depend not only on the inhibition of immunosuppressive pathways, but also on other mechanisms.